Following his work on the mRNA flu vaccine, Dr. Sehulong Robert Moraba also contributed to Moderna’s pipeline for maternal health. He served as a Sub-Investigator for the Phase 2 mRNA-1345-P201 trial, an observer-blind, placebo-controlled, dose-escalation study of an mRNA RSV vaccine in pregnant women.
This study (SAHPRA ref: 20240206) evaluated the vaccine’s reactogenicity, safety, and immunogenicity in mothers, as well as safety and immunogenicity in their infants. Dr. Moraba’s clinical oversight helped assess this promising platform’s potential to protect newborns through maternal immunization, a key public health strategy.
